| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0016 | AB073614 | ovarian cancer | microarray, qPCR, Western blot, knockdown, FCA etc. | ovarain cancer tissue, cell lines (A2780, Caov3, HO-8910, OVCAR3, SKOV3 etc.) | up-regulated | interaction | Results showed that AB073614 expression was significantly up-regulated in 85.3% (64/75) cancerous tissues compared with normal counterparts. Knockdown of AB073614 expression significantly inhibited cell proliferation and invasion, resulted in cell arrest in G1 phase of cell cycle and a dramatic increase of apoptosis. Finally, western blot assays indicated that lncRNA AB073614 may exert its function by targeting ERK1/2 and AKT-mediated signaling pathway. In conclusion, our study suggests that lncRNA AB073614 acts as a functional oncogene in OC development. | 26299803 | Lnc2Cancer |
| EL0030 | AC104699.1.1 | ovarian cancer | high-throughput molecular profiles | 399 Ovarian cancer (OV) patients | N/A | expression | Two protective lncRNAs, RP11-284N8.3.1 and AC104699.1.1, were not only differentially expressed throughout the progression of malignant OV but were also independently predictive of the survival of patients with different OV stages. A functional analysis of the two lncRNAs predicted their roles in immune system activation and other anti-tumor processes in the OV microenvironment. | 26629053 | |
| EL0224 | BACE1-AS | ovarian cancer | siRNA | human anisomycin-treated ovarian cancer stem cells (OCSCs) | up-regulated | interaction | lncRNA BACE1-AS as a novel target for anisomycin. Elevation of lncRNA BACE1-AS expression is a potential mechanism for suppressing human OCSC proliferation and invasion. | 26783004 | |
| EL0237 | BCYRN1 | ovarian cancer | ISH, Northern hybridization etc. | ovarian cancer tissue | up-regulated | expression | BC200 RNA was expressed in carcinomas of the breast, cervix, oesophagus, lung, ovary, parotid, and tongue, but not in corresponding normal tissues. | 9422992 | LncRNADisease Lnc2Cancer |
| EL0237 | BCYRN1 | ovarian cancer | ovarian cancer tissue and normal ovarian tissue samples | ovarian cancer tissue and normal ovarian tissue samples | up-regulated | N/A | tumor suppressive function in ovarian cancer by affecting cell proliferation | 26893717 | |
| EL0276 | CCAT1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL0293 | ceruloplasmin | ovarian cancer | knockdown | orthotopic mouse model of ovarian cancer | up-regulated | interaction | NRCP was highly upregulated in ovarian tumors, and knockdown of NRCP resulted in significantly increased apoptosis, decreased cell proliferation, and decreased glycolysis compared with control cancer cells. In an orthotopic mouse model of ovarian cancer, siNRCP delivered via a liposomal carrier significantly reduced tumor growth compared with control treatment. | 26686630 | |
| EL0486 | FALEC | ovarian cancer | knockdown | ovarian cancer cell lines | up-regulated | expression | These results demonstrate the utility of this integrated approach to identify oncogenic lncRNAs and suggest that FAL1 may represent a prognostic biomarker and therapeutic target in ovarian cancer. FAL1 is an oncogenic lncRNA that promotes cancer cell growth in part via repression of p21. | 25367941 | |
| EL0486 | FALEC | ovarian cancer | qPCR | N/A | N/A | interaction | FAL1 associates with the epigenetic repressor BMI1 and regulates its stability in order to modulate the transcription of a number of genes including CDKN1A. The oncogenic activity of FAL1 is partially attributable to its repression of p21. FAL1- specific siRNAs significantly inhibit tumor growth in vivo. | 25203321 | |
| EL0526 | GAS5 | ovarian cancer | microarray, qPCR, knockdown etc. | EOC tissue, cell lines (HO8910, A2780) | down-regulated | interaction | The data show that no significant differences of GAS5 expression were observed between normal ovarian epithelium and benign epithelial lesions; however, GAS5 expression was lower in EOC tissues compared with normal ovarian epithelial tissues, which was closely related to lymph node metastasis and tumor node metastasis stage. Finally, through mitochondrial potential and western blot analyses, GAS5 could disrupt mitochondrial membrane potential and promote BAX, BAK, cleaved-caspase 3 and cleaved-caspase 9 expression. | 26503132 | Lnc2Cancer |
| EL0556 | H19 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL0556 | H19 | ovarian cancer | microarray, qPCR, Western blot etc. | cell lines (OVCAR-3, OV-90 and SK-OV-3) | down-regulated | interaction | We find that overexpression of H1.3 decreases the growth rate and colony formation of OVCAR-3 cells. We identify histone H1.3 as a specific repressor for the noncoding oncogene H19. Overexpression of H1.3 suppresses H19 expression, and knockdown of H1.3 increases its expression in multiple ovarian epithelial cancer cell lines. Furthermore, we demonstrate that histone H1.3 overexpression leads to increased occupancy of H1.3 at the H19 regulator region encompassing the imprinting control region (ICR), concomitant with increased DNA methylation and reduced occupancy of the insulator protein CTCF at the ICR. Finally, we demonstrate that H1.3 overexpression and H19 knockdown synergistically decrease the growth rate of ovarian cancer cells | 25205099 | Lnc2Cancer |
| EL0556 | H19 | ovarian cancer | qPCR, knockdown etc. | cell lines (PC3, C2C12 etc.) | up-regulated | expression | H19 RNA was detected in 90% of patients with OCAF (Ovarian cancer ascites fluid ) as determined by ISH. Intratumoral injection of DTA-H19 into ectopically developed tumors caused 40% inhibition of tumor growth. | 19656414 | LncRNADisease Lnc2Cancer |
| EL0556 | H19 | ovarian cancer | qPCR, Western blot, knockdown etc. | ovarian cancer tissues and adjacent normal tissues, cell lines (SKOV3, OV90, TOV112D, ES2) | up-regulated | expression | Our results demonstrated that that H19 silencing inhibited OV90 and SKOV3 OC cell proliferation in vitro. Further investigation into the mechanisms responsible for the growth inhibitory effects by H19 silencing revealed that its knockdown resulted in the induction of cell cycle arrest and apoptosis through certain cell cycle-related and apoptosis-related proteins | 26617715 | Lnc2Cancer |
| EL0578 | HOTAIR | ovarian cancer | monitored double-strand breaks | recurrent platinum-resistant ovarian tumors vs primary ovarian tumors | N/A | N/A | HOTAIR expression results in sustained activation of DNA damage response (DDR) after platinum treatment; HOTAIR regulates activation of NF-κB | 27041570 | |
| EL0578 | HOTAIR | ovarian cancer | qPCR etc. | ovarian cancer tissue | up-regulated | N/A | The expression of HOTAIR in ovarian cancer tissue was higher than that in normal ovarian tissue. The expression was statistically higher in poorly differentiated ovarian cancer than poorly-moderately, moderately-well, and well-differentiated ones (1.65 +/- 0.41 vs. 0.39 +/- 0.14, P < 0.05). | 23600210 | Lnc2Cancer |
| EL0578 | HOTAIR | ovarian cancer | qPCR etc. | ovarian cancer tissue | up-regulated | expression | HOTAIR expression was significantly associated with poor survival in carboplatin-treated patients with adjusted hazard ratios for death of 3.64 in the discovery and 1.63 in the validation set. This effect was not seen in patients who did not receive carboplatin. HOTAIR expression or its surrogate DNAme signature predicted poor outcome in all additional sets of carboplatin-treated ovarian cancer patients while HOTAIR expressors responded preferentially to cisplatin. | 26497652 | Lnc2Cancer |
| EL0578 | HOTAIR | ovarian cancer | qPCR, Western blot, knockdown etc. | epithelial ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | up-regulated | expression | Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer. | 24662839 | LncRNADisease Lnc2Cancer |
| EL0578 | HOTAIR | ovarian cancer | qPCR, Western blot, knockdown etc. | cell lines (SKOV3) | up-regulated | interaction | The results demonstrated that the HOTAIR expression in clinical EOC tissues and SKOV3 CD117(+)CD44(+)CSCs was higher than in SKOV3 tumor tissues and non-CD117(+)CD44(+)CSCs. | 25792974 | Lnc2Cancer |
| EL0578 | HOTAIR | ovarian cancer | qPCR, Western blot, knockdown, MTT assay etc. | ovarian cancer tissue, cell lines (A2780, 3AO, OVCAR3, SKOV3, HO-8910) | up-regulated | interaction | HOTAIR overexpression promoted cell cycle progression (and thus cell proliferation) by activating the Wnt/β-Catenin signaling pathway. Likewise, knockdown of HOTAIR suppressed cell proliferation and arrested cell cycle at G1 phase via inhibition of Wnt/β-Catenin signaling. Moreover, the results of primary culture demonstrated that elevated HOTAIR expression correlated positively with chemoresistance in ovarian cancer. | 26341496 | Lnc2Cancer |
| EL0584 | HOXA11-AS | ovarian cancer | qPCR, Western blot etc. | ovarian cancer tissue | down-regulated | mutation | Functional studies of ectopic expression of HOXA11-AS minor allele T in EOC cells showed decreased survival, proliferation, migration, and invasion compared to common allele A expression. Additionally, stable expression of HOXA11-AS minor allele T reduced primary tumor growth in mouse xenograft models to a greater extent than common allele A. Furthermore, HOXA11-AS expression levels were significantly lower in human EOC tumors than normal ovarian tissues (p < 0.05), suggesting that HOXA11-AS has a tumor suppressor function in EOC which may be enhanced by the T allele | 26430965 | Lnc2Cancer |
| EL0671 | LINC00942 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL0843 | LSINCT5 | ovarian cancer | N/A | N/A | N/A | expression | Ovarian and breast tumours have also been associated with the expression of the LSINCT5 lncRNA; this transcript acts to target several other transcripts, including the antisense RNA NEAT-1 and the PSPC1 gene, which codes for a splicing regulatory factor | 22817756 | LncRNADisease |
| EL0843 | LSINCT5 | ovarian cancer | qPCR, Northern blot, etc. | cell lines (OVCAR5, NHBE etc.) | up-regulated | expression | LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues. | 21532345 | LncRNADisease Lnc2Cancer |
| EL0843 | LSINCT5 | ovarian cancer | qPCR, Northern blot, knock-down, Microarray | human bronchial epithelial (NHBE) cells, breast cancer cell line, ovarian cancer cell line | up-regulated | expression | knock-down of LSINCT5 expression decreased proliferation in human breast and ovarian cancer cells; Using a genome tiling array to identify noncoding sequences upregulated in normal human bronchial epithelial (NHBE) cells exposed to a DNA-damaging tobacco carcinogen | 26323562 | |
| EL0853 | MALAT1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL0932 | MNX1-AS1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL0973 | NEAT1 | ovarian cancer | knockdown of NEAT1_1 | OC patients and OVCAR-3 cell lines | up-regulated | N/A | lncRNA NEAT1, whose expression was collaboratively controlled by HuR and miR-124-3p, could regulate ovarian carcinogenesis | 27075229 | |
| EL1027 | OVAAL | ovarian cancer | RNA-seq, qPCR etc. | ovarian cancer tissue | down-regulated | N/A | OVAL expression was low or absent in both normal fallopian tube (Figure S3 in File S1) and in the majority of tumors, including most cases with wide 1q amplification. However, focal amplification of the OVAL locus coincided strikingly with OVAL transcriptional activation. | 24265805 | Lnc2Cancer |
| EL1102 | PVT1 | ovarian cancer | qPCR etc. | cell lines (A2780, DOV13, PA-1 etc.) | up-regulated | expression | Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. | 17908964 | LncRNADisease Lnc2Cancer |
| EL1102 | PVT1 | ovarian cancer | qRT-PCR | ovarian cancer tissues of cisplatin-resistant patients and cisplatin-sensitive patients | up-regulated | N/A | Overexpression of LncRNA PVT1 in ovarian cancer promotes cisplatin resistance by regulating apoptotic pathways | 26884974 | |
| EL1137 | RP11-284N8.3.1 | ovarian cancer | high-throughput molecular profiles | 399 Ovarian cancer (OV) patients | N/A | expression | Two protective lncRNAs, RP11-284N8.3.1 and AC104699.1.1, were not only differentially expressed throughout the progression of malignant OV but were also independently predictive of the survival of patients with different OV stages. A functional analysis of the two lncRNAs predicted their roles in immune system activation and other anti-tumor processes in the OV microenvironment. | 26629053 | |
| EL1241 | SRA1 | ovarian cancer | N/A | N/A | N/A | regulation | Co-activator of steroid Receptors & other transcription Factors; associate with metastasis | 24499465 | LncRNADisease |
| EL1269 | TC1500845 | ovarian cancer | microarray, qPCR etc. | epithelial ovarian cancer tissue, cell lines (SKOV3 etc.) | up-regulated | N/A | The results revealed that the expression levels of TC0100223 and TC0101686 were significantly downregulated by E2, whereas TC1500845 and TC0101441 were significantly upregulated by E2 in SKOV3 cells, consistent with the microarray results. | 24481591 | LncRNADisease Lnc2Cancer |
| EL1431 | UCA1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL1448 | VPS9D1-AS1 | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) | down-regulated | N/A | The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. | 24379988 | Lnc2Cancer |
| EL1459 | XIST | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (ALST, CAOV3, OVCA3 etc.) | down-regulated | N/A | The clinical relevance of this observation is demonstrated by the strong association between XIST RNA levels and disease-free periods of ovarian cancer patients in a group of 21 ovarian cancer cases with Taxol in the therapeutic regiments. Cytogenetic studies on ovarian cancer cell lines indicated that loss of inactive X chromosome is one mechanism for the loss of XIST transcripts in the cell lines. Our data suggest that XIST expression may be a potential marker for chemotherapeutic responses in ovarian cancer. | 12492109 | Lnc2Cancer |
| EL1459 | XIST | ovarian cancer | microarray, qPCR etc. | ovarian cancer tissue, cell lines (NOSE, EOC etc.) | down-regulated | N/A | A series of malignant ovarian tumor samples were investigated for XIST expression. XIST expression was detectable by RT-PCR in the majority of EOC samples tested but was expressed at very low levels in four of 15 (27%) EOC samples, TOV921G, TOV1118D, TOV837, and TOV1054G. | 17143508 | Lnc2Cancer |